Share on StockTwits
 

Shares of Johnson & Johnson (NYSE:JNJ) have received an average rating of “Hold” from the twenty brokerages that are presently covering the stock, AR Network reports. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have given a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $78.67.

Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.69% during mid-day trading on Thursday, hitting $92.27. The stock had a trading volume of 3,356,461 shares. Johnson & Johnson has a one year low of $75.50 and a one year high of $95.99. The stock’s 50-day moving average is $91.83 and its 200-day moving average is $91.18. The company has a market cap of $260.3 billion and a price-to-earnings ratio of 19.06.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, January 21st. The company reported $1.24 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.20 by $0.04. The company had revenue of $18.40 billion for the quarter, compared to the consensus estimate of $17.95 billion. During the same quarter last year, the company posted $1.19 earnings per share. Johnson & Johnson’s revenue was up 4.5% compared to the same quarter last year. On average, analysts predict that Johnson & Johnson will post $5.83 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Johnson & Johnson in a research note on Monday. They now have a $97.00 price target on the stock. Separately, analysts at Guggenheim cut their price target on shares of Johnson & Johnson from $60.00 to $58.00 in a research note on Thursday, February 6th. Finally, analysts at Ned Davis Research upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating in a research note on Monday, January 27th.

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a broad range of products in the health care field.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.